Annacarolina da Silva
Assistant Professor of Pathology and Laboratory Medicine
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
About
Annacarolina da Silva is an Assistant Professor of Pathology and Laboratory Medicine at Weill Cornell Medical College, USA. Her research focuses on the mechanisms of cancer, specifically in areas such as pancreatic ductal adenocarcinoma and colorectal carcinoma. Recent publications include studies on leukocyte heterogeneity in pancreatic cancer and the association of Fusobacterium nucleatum with T-cell subsets in colorectal cancer. Additionally, she has contributed to the understanding of morphologic features in mucinous ovarian tumors and the clinical implications of insulin-like growth factor-1 receptor expression in cancer outcomes.
Articles (6)
Purpose: Approximately 8-10% of pancreatic ductal adenocarcinomas (PDAC) do not harbor mutations in KRAS. Understanding the unique molecular and clinical features of this subset of pancreatic cancer is important to guide patient stratification for clinical trials of molecularly targeted agents. Experimental Design: We analyzed a single-institution cohort of 795 exocrine pancreatic cancer cases (including 785 PDAC cases) with a targeted multi-gene sequencing panel and identified 73 patients (9.2%) with KRAS wild-type (WT) pancreatic cancer. Results: Overall, 43.8% (32/73) of KRAS WT cases had evidence of an alternative driver of the mitogen activated kinase (MAPK) pathway, including BRAF mutations and in-frame deletions and receptor-tyrosine kinase (RTK) fusions. Conversely, 56.2% of cases did not harbor a clear MAPK driver alteration, but 29.3% of these MAPK-negative KRAS WT cases (12/41) demonstrated activating alterations in other oncogenic drivers such as GNAS, MYC, PIK3CA and CTNNB1. We demonstrate potent efficacy of pan-RAF and MEK inhibition in patient-derived organoid (PDO) models carrying BRAF in-frame deletions. Moreover, we demonstrate durable clinical benefit of targeted therapy in a patient harboring a KRAS WT tumor with a ROS1fusion. Clinically, patients with KRAS WT tumors were significantly younger in age of onset (Median Age: 62.6 vs. 65.7 years , p = 0.037). SMAD4 mutations were associated with a particularly poor prognosis in KRAS WT cases. Conclusions: This study defines the genomic underpinnings of KRAS WT pancreatic cancer and highlights potential therapeutic avenues for future investigation in molecularly directed clinical trials.
Year:
2024
Purpose: Approximately 8-10% of pancreatic ductal adenocarcinomas (PDAC) do not harbor mutations in KRAS. Understanding the unique molecular and clinical features of this subset of pancreatic cancer is important to guide patient stratification for clinical trials of molecularly targeted agents. Experimental Design: We analyzed a single-institution cohort of 795 exocrine pancreatic cancer cases (including 785 PDAC cases) with a targeted multi-gene sequencing panel and identified 73 patients (9.2%) with KRAS wild-type (WT) pancreatic cancer. Results: Overall, 43.8% (32/73) of KRAS WT cases had evidence of an alternative driver of the mitogen activated kinase (MAPK) pathway, including BRAF mutations and in-frame deletions and receptor-tyrosine kinase (RTK) fusions. Conversely, 56.2% of cases did not harbor a clear MAPK driver alteration, but 29.3% of these MAPK-negative KRAS WT cases (12/41) demonstrated activating alterations in other oncogenic drivers such as GNAS, MYC, PIK3CA and CTNNB1. We demonstrate potent efficacy of pan-RAF and MEK inhibition in patient-derived organoid (PDO) models carrying BRAF in-frame deletions. Moreover, we demonstrate durable clinical benefit of targeted therapy in a patient harboring a KRAS WT tumor with a ROS1fusion. Clinically, patients with KRAS WT tumors were significantly younger in age of onset (Median Age: 62.6 vs. 65.7 years , p = 0.037). SMAD4 mutations were associated with a particularly poor prognosis in KRAS WT cases. Conclusions: This study defines the genomic underpinnings of KRAS WT pancreatic cancer and highlights potential therapeutic avenues for future investigation in molecularly directed clinical trials.
Year:
2024
Year:
2021
Year:
2021
Year:
2021
Year:
2020
Collaborators (9)
Hersh Gupta
Dana-Farber Cancer Institute
Kimmie Ng
Associate Professor of Medicine, Harvard Medical School
Dana-Farber Cancer Institute
Andrew D Cherniack
Group Leader
Dana-Farber Cancer Institute
Jeffrey Clark
Associate Professor
Harvard University
Srivatsan Raghavan
Assistant Professor
Dana-Farber Cancer Institute
Elizabeth Cohen
Dana-Farber Cancer Institute
Chen Yuan
Assistant Professor
Cedars-Sinai Medical Center
Michael Rosenthal
Brigham and Women's Hospital
Matthew Meyerson
Director, Center for Cancer Genomics
Dana-Farber Cancer Institute
Make your next move.
Prepare your application
Review drafts before you send them.